Treating an Advanced Combined Hepatocellular-Cholangiocarcinoma with a Multikinase Inhibitor

Area of Science:

• Hepatobiliary oncology
• Cancer biology
• Translational medicine

Background:

• Combined hepatocellular-cholangiocarcinoma (cHCC-CC) presents a diagnostic and therapeutic challenge due to its mixed histology and aggressive nature.
• Optimal systemic treatment for advanced or metastatic cHCC-CC remains undefined, often necessitating the use of regimens approved for either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC).

Observation:

• A male patient in his 50s with advanced cHCC-CC was diagnosed with lymph node and adrenal metastasis, alongside extensive portal vein tumor thrombosis.
• The patient initiated treatment with lenvatinib, a multi-kinase inhibitor, as a first-line systemic therapy.

Findings:

• This case highlights the clinical application of lenvatinib in a patient with advanced, metastatic cHCC-CC.
• The study underscores the need for further research into effective systemic treatments for this rare liver cancer subtype.

Implications:

• Lenvatinib may represent a viable therapeutic option for patients with advanced cHCC-CC, warranting further clinical investigation.
• Understanding treatment responses in rare cancers like cHCC-CC can inform future clinical trial designs and therapeutic strategies.